INTEGRATED FILING — Other than Banks



General information about company

Scrip code 000000
NSE Symbol SANGANI
MSEI Symbol NOTLISTED
ISIN INE0OVI01010
Name of Company SANGANI HOSPITALS LIMITED
Type of company SME
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 30-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 21-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Half Yearly
Reporting Quarter Yearly
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment HEALTHCARE
Start date and time of board meeting 30-May-2025   12:00:00
End date and time of board meeting 30-May-2025   23:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? No
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
(III) Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-05-30
Indicate Company website link for updated RPT policy of the Company https://sanganihospitals.com/wp-content/uploads/2024/11/3.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? Yes


Financial Results — Other than Bank
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Oct-2024 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Revenue From Operations
Revenue from operations 90120000 167990000
Other income 7928000 15707000
Total Income 98048000 183697000
2 Expenses
(a) Cost of materials consumed 34736000 57919000
(b) Purchases of stock-in-trade 0 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -1134000 -3774000
(d) Employee benefit expense 21377000 39981000
(e) Finance costs 0 0
(f) Depreciation and amortisation expense 4235000 5936000
(g) Other Expenses
1 other 27006000 49008000
Total other expenses 27006000 49008000
Total expenses 86220000 149070000
3 Profit before exceptional and extraordinary items and tax 11828000 34627000
4 Exceptional items 0 0
5 Profit before extraordinary items and tax 11828000 34627000
6 Extraordinary items 0 0
7 Profit before tax 11828000 34627000
8 Tax Expense
Current tax 2415000 6910000
Deferred tax 544000 1769000
Total tax expenses 2959000 8679000
9 Net Profit Loss for the period from continuing operations 8869000 25948000
10 Profit (loss) from discontinuing operations before tax 0 0
11 Tax expense of discontinuing operations 0 0
12 Net profit (loss) from discontinuing operation after tax 0 0
13 Profit (loss) for period before minority interest 8869000 25948000
14 Share of profit (loss) of associates
15 Profit (loss) of minority interest
16 Net profit (Loss) for the period 8869000 25948000
17 Details of equity share capital
Paid-up equity share capital 137770000 137770000
Face value of equity share capital 10 10
18 Reserves excluding revaluation reserve 0
19 Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.64 1.88
Diluted earnings (loss) per share from continuing and discontinued operations 0.64 1.88
20 Debt equity ratio 0.0 0.0
21 Debt service coverage ratio 0.0 0.0
22 Interest service coverage ratio 0.0 0.0
23 Disclosure of notes on financial results Textual Information(1)


Text Block
Textual Information(1) 1.The above results were reviewed and recommended by the Audit Committee, at its meeting held on 30th May, 2025 for approval by the Board and these results were approved and taken on record at the meeting of the Board of Directors of the Company held on that date. The above result is subjected to Limited Review by the Statutory Auditors of the Company, as required under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. These results have been prepared in accordance with the recognition and measurement principles laid down in AS-25 Interim Financials Reporting presribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued thereunder and other accounting principles generally accepted in India. 3. The figures for the preceding half year ended on 31st March, 2025 as reported in these financial result, are the balancing figures between audited figures in respect of the full financial year ended on 31st March, 2025 and based on the Management Certified Accounts which are not subjected to Limited Review by the Statutory Auditors. 4. The Company is engaged in the business of healthcare related services. In the management opinion, this is the only segment and hence there are no separate reportable segment as per AS-17 on Segement Reporting. 5. The Compnay has completed its Initial Public Offering ( IPO ) of 37,92,000 new Equity Shares of Rs. 10 each at premium of Rs. 30 each per Equity Shares aggregating to Rs. 1516.80 lakhs. Pursuant to the IPO, the Equity Shares of the Company have got listed on NSE Emerge Platform on August 17, 2023. 6. The details of utilization of IPO Proceeds are as per the table set forth below: S. No. Particulars Planned as per Prospectus (Rs. In Lakhs) Actual Utilization of proceeds upto 31-03-2025 (Rs. In lakhs) Pending to be utilised (Rs. In Lakhs) 1 Capital Expenditure for expansion in Keshod Hospital 809.58 216.89 592.69 2 Capital Expenditure for expansion in Veraval Hospital 319.02 55.47 263.55 3 General Corporate Purpose 161.10 11.86 149.24 4 Issue expenses 227.10 227.1 - Total Proceeds from the Issue 1,516.80 511.32 1,005.48 7. The above financial results are available on the website of the company i.e. www.sanganihospitals.com and on the website of emerge platform of National Stock Exchange i.e. www.nseindia.com 8.Figures for previous half year/ year have been regrouped wherever necessary to make them comparable.


Remarks
20 Debt equity ratio
21 Debt service coverage ratio
22 Interest service coverage ratio


Cash flow statement — indirect
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
1 Statement of cash flows
Cash flows from used in operating activities
Profit before extraordinary items and tax 34627000
2 Adjustments for reconcile profit (loss)
Adjustments to profit (loss)
Adjustments for finance costs 0
Adjustments for depreciation and amortisation expense 5936000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for share-based payments 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments to profit (loss) 5936000
3 Adjustments for working capital
Adjustments for decrease (increase) in inventories -3774000
Adjustments for decrease (increase) in trade receivables -5818000
Adjustments for decrease (increase) in other current assets -8546000
Adjustments for increase (decrease) in trade payables -910000
Adjustments for increase (decrease) in other current liabilities 10318000
Adjustments for provisions -978000
Total adjustments for working capital -9708000
Total adjustments for reconcile profit (loss) -3772000
Net cash flows from (used in) operations 30855000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 6960000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities before extraordinary items 23895000
Proceeds from extraordinary items 0
Payment for extraordinary items 0
Net cash flows from (used in) operating activities 23895000
4 Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property plant and equipment 0
Purchase of property plant and equipment 10874000
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 0
Income taxes paid (refund) 0
Other inflows (outflows) of cash 194000
Proceeds from government grants 0
Net cash flows from (used in) investing activities before extraordinary items -10680000
Proceeds from extraordinary items 0
Payment for extraordinary items 0
Net cash flows from (used in) investing activities -10680000
Cash flows from used in financing activities
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 0
Dividends paid 0
Interest paid 0
Income taxes paid (refund) 0
Other inflows (outflows) of cash -22574000
Net cash flows from (used in) financing activities before extraordinary items -22574000
Proceeds from extraordinary items 0
Payment for extraordinary items 0
Net cash flows from (used in) financing activities -22574000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -9359000
6 Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -9359000
Cash and cash equivalents cash flow statement at beginning of period 186150000
Cash and cash equivalents cash flow statement at end of period 176791000


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Equity and liabilities
1 Shareholders' funds
Share capital 137770000
Reserves and surplus 223086000
Money received against share warrants 0
Total shareholders' funds 360856000
2 Share application money pending allotment 0
3 Deferred government grants 0
4 Minority interest
5 Non-current liabilities
Long-term borrowings 0
Deferred tax liabilities (net) 4716000
Foreign currency monetary item translation difference liability account 0
Other long-term liabilities 0
Long-term provisions 907000
Total non-current liabilities 5623000
6 Current liabilities
Short-term borrowings 0
Trade Payables
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 6593000
Total Trade payable 6593000
Other current liabilities 12669000
Short-term provisions 875000
Total current liabilities 20137000
Total equity and liabilities 386616000
Assets
1 Non-current assets
i Property, Plant and Equipment and Intangible assets
Property, Plant and Equipment 131642000
Producing properties 0
Intangible assets 0
Preproducing properties 0
Property, Plant and Equipment capital work-in-progress 0
Intangible assets under development or work-in-progress 0
Total Property, Plant and Equipment and Intangible assets 131642000
ii Non-current investments 0
v Deferred tax assets (net) 0
vi Foreign currency monetary item translation difference asset account 0
vii Long-term loans and advances 27463000
viii Other non-current assets 0
Total non-current assets 159105000
Current assets
Current investments 8188000
Inventories 9137000
Trade receivables 23766000
Cash and cash equivalents 0
Bank balance other than cash and cash equivalents 176791000
Short-term loans and advances 0
Other current assets 9629000
Total current assets 227511000
Total assets 386616000
Disclosure of notes on assets and liabilities


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Oct-2024 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets
Net Segment Asset
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities
Net Segment Liabilities
Disclosure of notes on segments




Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 KUMBHAT & COMPANY Yes 30-Sep-2026


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)
Mode of Fund Raising Public Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 17-Aug-2023
Amount Raised 151680000
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation NA
Comments of the Audit Committee after review
Comments of the auditors, if any
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Capital Expenditure for expansion in Keshod Hospital No 80958000 0 21689000 0
2 Capital Expenditure for expansion in Veraval Hospital No 31902000 0 5547000 0
3 General Corporate Purpose No 16110000 0 1186000 0
4 Issue Expenses No 22710000 0 22710000 0


Signatory Details
Name of signatory CHANDNI SANGANI
Designation of person Chief Financial Officer
Place KESHOD, JUNAGADH
Date 30-May-2025


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 SANAGNI HOSPITALS LIMITED AJAYKUMAR SANGANI DIRECTTOR Remuneration NIL 4564000 4000 352000
2 SANAGNI HOSPITALS LIMITED RAJESHKUMAR SANGANI DIRECTTOR Remuneration NIL 4564000 4000 352000
3 SANAGNI HOSPITALS LIMITED KAMALKUMAR SANGANI DIRECTTOR Remuneration NIL 4564000 4000 352000
4 SANAGNI HOSPITALS LIMITED CHANDNI SANGANI RELATIVE OF DIRECTOR Remuneration NIL 4564000 4000 352000
5 SANAGNI HOSPITALS LIMITED VAISHALI SANGANI RELATIVE OF DIRECTOR Remuneration NIL 4564000 4000 352000
6 SANAGNI HOSPITALS LIMITED GOPI SANGANI RELATIVE OF DIRECTOR Remuneration NIL 4564000 4000 352000
7 SANAGNI HOSPITALS LIMITED ANKUR DISTRIBUTOR SUBSIDIARY FIRM Sale of goods or services NIL 0 33000 14000
8 SANAGNI HOSPITALS LIMITED ANKUR DISTRIBUTOR SUBSIDIARY FIRM Purchase of goods or services NIL 7905000 2000 2000
Total value of transaction during the reporting period 35289000





Format for Disclosing Outstanding Default on Loans and Debt Securities
Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date 0
B Of the total amount outstanding, amount of default as on date 0
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date 0
B Of the total amount outstanding, amount of default as on date 0
3. Total financial indebtedness of the listed entity including short-term and long-term debt 0